Management of severe COPD exacerbations: Focus on beclomethasone dipropionate/ formoterol/glycopyrronium bromide

Marco Mantero, Dejan Radovanovic, Pierachille Santus, Francesco Blasi

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The major determinant of the decline in lung function, quality of life, and the increased mortality risk in patients with COPD is represented by severe acute exacerbations of the disease, that is, those requiring patients’ hospitalization, constituting a substantial social and health care burden in terms of morbidity and medical resource utilization. Different long-term therapeutic strategies have been proposed so far in order to prevent and/or reduce the clinical and social impact of these events, the majority of which were extrapolated from trials initially focused on the effect of long-acting muscarinic antagonist and subsequently on the efficacy of long-acting β2-agonists in combination or not with inhaled corticosteroids. The option to employ all three classes of molecules combined, despite the limited amount of evidence in our possession, represents a choice currently proposed by international guidelines; however, current recommendations are often based mainly on observational studies or on the results of secondary outcomes in randomized controlled trials. The present narrative review evaluates the available trials that investigated the efficacy of inhaled therapy to prevent COPD exacerbations and especially severe ones, with a particular focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide fixed dose combination, which is the first treatment that comprises all the three drug classes, specifically tested for the prevention of moderate and severe COPD exacerbations.

Original languageEnglish
Pages (from-to)2319-2333
Number of pages15
JournalInternational Journal of COPD
Volume13
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Glycopyrrolate
Beclomethasone
Chronic Obstructive Pulmonary Disease
Muscarinic Antagonists
Acute Disease
Social Change
Observational Studies
Adrenal Cortex Hormones
Hospitalization
Therapeutics
Randomized Controlled Trials
Quality of Life
Guidelines
Morbidity
Delivery of Health Care
Lung
Mortality
Pharmaceutical Preparations
Formoterol Fumarate

Keywords

  • COPD
  • Formoterol
  • Glycopyrronium
  • Hospitalization
  • Inhaled corticosteroids
  • Triple therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Management of severe COPD exacerbations : Focus on beclomethasone dipropionate/ formoterol/glycopyrronium bromide. / Mantero, Marco; Radovanovic, Dejan; Santus, Pierachille; Blasi, Francesco.

In: International Journal of COPD, Vol. 13, 01.01.2018, p. 2319-2333.

Research output: Contribution to journalReview article

@article{76b933efd8d64cf6935b7db2f8a60cfb,
title = "Management of severe COPD exacerbations: Focus on beclomethasone dipropionate/ formoterol/glycopyrronium bromide",
abstract = "The major determinant of the decline in lung function, quality of life, and the increased mortality risk in patients with COPD is represented by severe acute exacerbations of the disease, that is, those requiring patients’ hospitalization, constituting a substantial social and health care burden in terms of morbidity and medical resource utilization. Different long-term therapeutic strategies have been proposed so far in order to prevent and/or reduce the clinical and social impact of these events, the majority of which were extrapolated from trials initially focused on the effect of long-acting muscarinic antagonist and subsequently on the efficacy of long-acting β2-agonists in combination or not with inhaled corticosteroids. The option to employ all three classes of molecules combined, despite the limited amount of evidence in our possession, represents a choice currently proposed by international guidelines; however, current recommendations are often based mainly on observational studies or on the results of secondary outcomes in randomized controlled trials. The present narrative review evaluates the available trials that investigated the efficacy of inhaled therapy to prevent COPD exacerbations and especially severe ones, with a particular focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide fixed dose combination, which is the first treatment that comprises all the three drug classes, specifically tested for the prevention of moderate and severe COPD exacerbations.",
keywords = "COPD, Formoterol, Glycopyrronium, Hospitalization, Inhaled corticosteroids, Triple therapy",
author = "Marco Mantero and Dejan Radovanovic and Pierachille Santus and Francesco Blasi",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/COPD.S147484",
language = "English",
volume = "13",
pages = "2319--2333",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Management of severe COPD exacerbations

T2 - Focus on beclomethasone dipropionate/ formoterol/glycopyrronium bromide

AU - Mantero, Marco

AU - Radovanovic, Dejan

AU - Santus, Pierachille

AU - Blasi, Francesco

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The major determinant of the decline in lung function, quality of life, and the increased mortality risk in patients with COPD is represented by severe acute exacerbations of the disease, that is, those requiring patients’ hospitalization, constituting a substantial social and health care burden in terms of morbidity and medical resource utilization. Different long-term therapeutic strategies have been proposed so far in order to prevent and/or reduce the clinical and social impact of these events, the majority of which were extrapolated from trials initially focused on the effect of long-acting muscarinic antagonist and subsequently on the efficacy of long-acting β2-agonists in combination or not with inhaled corticosteroids. The option to employ all three classes of molecules combined, despite the limited amount of evidence in our possession, represents a choice currently proposed by international guidelines; however, current recommendations are often based mainly on observational studies or on the results of secondary outcomes in randomized controlled trials. The present narrative review evaluates the available trials that investigated the efficacy of inhaled therapy to prevent COPD exacerbations and especially severe ones, with a particular focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide fixed dose combination, which is the first treatment that comprises all the three drug classes, specifically tested for the prevention of moderate and severe COPD exacerbations.

AB - The major determinant of the decline in lung function, quality of life, and the increased mortality risk in patients with COPD is represented by severe acute exacerbations of the disease, that is, those requiring patients’ hospitalization, constituting a substantial social and health care burden in terms of morbidity and medical resource utilization. Different long-term therapeutic strategies have been proposed so far in order to prevent and/or reduce the clinical and social impact of these events, the majority of which were extrapolated from trials initially focused on the effect of long-acting muscarinic antagonist and subsequently on the efficacy of long-acting β2-agonists in combination or not with inhaled corticosteroids. The option to employ all three classes of molecules combined, despite the limited amount of evidence in our possession, represents a choice currently proposed by international guidelines; however, current recommendations are often based mainly on observational studies or on the results of secondary outcomes in randomized controlled trials. The present narrative review evaluates the available trials that investigated the efficacy of inhaled therapy to prevent COPD exacerbations and especially severe ones, with a particular focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide fixed dose combination, which is the first treatment that comprises all the three drug classes, specifically tested for the prevention of moderate and severe COPD exacerbations.

KW - COPD

KW - Formoterol

KW - Glycopyrronium

KW - Hospitalization

KW - Inhaled corticosteroids

KW - Triple therapy

UR - http://www.scopus.com/inward/record.url?scp=85058438056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058438056&partnerID=8YFLogxK

U2 - 10.2147/COPD.S147484

DO - 10.2147/COPD.S147484

M3 - Review article

AN - SCOPUS:85058438056

VL - 13

SP - 2319

EP - 2333

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

ER -